Treatment and outcomes for patients with depression who are partial responders to SSRI treatment: Post-hoc analysis findings from the FINDER European observational study

Journal of Affective Disorders

Volumn 169, Issue , 2014, Pages 149-156

  Lenox Smith, A ^a   Martinez, J M ^a   Perahia, D ^a   Dowsett, S A ^a   Dennehy, E B ^a,b   Lopez Romero, P ^c   Demyttenaere, K ^d  

^a ELI LILLY AND COMPANY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (Spain)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Depression; Observational study; Partial response; Remission

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREVALENCE; QUALITY OF LIFE; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; COHORT ANALYSIS; DEPRESSIVE DISORDER; EUROPE; MIDDLE AGED; PSYCHOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COHORT STUDIES; DEPRESSION; DEPRESSIVE DISORDER; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84908460251     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.08.003     Document Type: Article

References (35)

1. American Psychiatric Association Practice Guideline for the Treatment of Patients With Major Depressive Disorder 2010 American Psychiatric Association http://psychiatryonline.org/data/Books/prac/PG-Depression3rdEd.pdf
2. M. Bauer, B.U. Monz, A.L. Montejo, D. Quail, N. Dantchev, K. Demyttenaere, A. Garcia-Cebrian, L. Grassi, D.G.S. Perahia, C. Reed, and A. Tylee Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study Eur. Psychiatry 23 2008 66 73
3. S. Byford, B. Barrett, N. Despiegel, and A. Wade Impact of treatment success on health service use and cost in depression Pharmacoeconomics 29 2011 157 170
4. T.E. Chang, Y. Jing, A.S. Yeung, S.K. Brenneman, I. Kalsekar, T. Hebden, R. McQuade, L. Baer, J.L. Kurlander, A.K. Watkins, J.A. Siebenaler, and M.l. Fava Effect of communicating depression severity on physician prescribing patterns: findings from the Clinical Outcomes in Measurement-based Treatment (COMET) trial Gen. Hosp. Psychiatry 34 2012 105 112
5. P.K. Corey-Lisle, R. Nash, P. Stang, and R. Swindle Response, partial response, and nonresponse in primary care treatment of depression Arch. Intern. Med. 164 2004 1197 1204
6. E.B. Dennehy, L.B. Marangell, J. Martinez, G.K. Balasubramani, and S.R. Wisniewski Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STARD J Psych. 20 2014 178 187
7. J.I. Escobar, M. Rubio-Stipec, G. Canino, and M. Karno Somatic symptom index (SSI): a new and abridged somatization construct. Prevalence and epidemiological correlates in two large community samples J. Nerv. Ment. Dis. 177 1989 140 146
8. J.C. Fournier, R.J. DeRubeis, R.C. Shelton, S.D. Hollon, J.D. Amsterdam, and R. Gallop Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression J. Consult. Clin. Psychol. 77 2009 775 787
9. E. Frank, R.F. Prien, R.B. Jarrett, M.B. Keller, D.J. Kupfer, P.W. Lavori, A.J. Rush, and M.M. Weissman Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence Arch. Gen. Psychiatry 48 1991 851 855
10. T. Greco, G. Eckert, and K. Kroenke The outcome of physical symptoms with treatment of depression J. Gen. Intern. Med. 19 2004 813 818
11. A. Garcia-Cebrian, M. Bauer, A.L. Montejo, N. Dantchev, K. Demyttenaere, P. Gandhi, L. Grassi, B.U. Monz, D.G.S. Perahia, D. Quail, and A. Tylee Factors influencing depression endpoints research (FINDER): study design and population characteristics Eur. Psychiatry 23 2008 57 65
12. R.H. Howland, M.G. Wilson, S.G. Kornstein, A.H. Clayton, M.H. Trivedi, M.M. Wohlreich, and M. Fava Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression Ann. Clin. Psychiatry 20 2008 209 218
13. R.H. Howland, A.J. Rush, S.R. Wisniewski, M.H. Trivedi, D. Warden, M. Fava, L.L. Davis, G.K. Balasubramani, P.J. McGrath, and S.R. Berman Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome Drug Alcohol Depend. 99 2009 248 260
14. M. Keller Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond JAMA 289 2003 3152 3160
15. K.S. Kendler, L.M. Thornton, and C.O. Gardner Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis Am. J. Psychiatry 157 2000 1243 1251
16. R.C. Kessler, and R.G. Frank The impact of psychiatric disorders on work loss days Psychol. Med. 27 1997 861 873
17. A.C. Kouzis, and W.W. Eaton Emotional disability days: prevalence and predictors Am. J. Public Health 84 1994 1304 1307
18. D.J. Kupfer Long-term treatment of depression J. Clin. Psychiatry 52 Suppl. 5 1991 S28 S34
19. J.A. Mauskopf, G.E. Simon, K. Anupama, C. Nimsch, E. Dunayevich, and A. Cameron Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder Depress. Anxiety 26 2009 83 97
20. S.M. McClintock, M.M. Husain, S.R. Wisniewski, A.A. Nierenberg, J.W. Stewart, M.H. Trivedi, I. Cook, D. Morris, D. Warden, and A.J. Rush Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication J. Clin. Psychopharmacol. 31 2011 180 186
21. ®): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs Med. Care 31 1993 247 263
22. R.S. McIntyre, and C. O'Donovan The human cost of not achieving full remission in depression Can. J. Psychiatry 49 3 suppl 1 2004 10s 16s
23. I.W. Miller, G.I. Keitner, A.F. Schatzberg, D.N. Klein, M.E. Thase, A.J. Rush, J.C. Markowitz, D.S. Schlager, S.G. Kornstein, S.M. Davis, W.M. Harrison, and M.B. Keller The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine J. Clin. Psychiatry 59 1998 608 619
24. NICE Depression in adults: The treatment and management of depression in adults National Institute for Health and Care Excellence (NICE) Clinical Guidelines 2009
25. A.A. Nierenberg, M.M. Husain, M.H. Trivedi, M. Fava, D. Warden, S.R. Wisniewski, S. Miyahara, and A.J. Rush Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STARD report Psychol. Med. 40 2010 41 50
26. E.S. Paykel, R. Ramana, Z. Cooper, H. Hayhurst, J. Kerr, and A. Barocka Residual symptoms after partial remission: an important outcome in depression Psychol. Med. 25 1995 1171 1180
27. C. Reed, B.U. Monz, D.G.S. Perahia, P. Gandhi, M. Bauer, N. Dantchev, K. Demyttenaere, A. Garcia-Cebrian, L. Grassi, D. Quail, A. Tylee, and A.L. Montejo Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER J. Affect. Disord. 113 2009 296 396
28. I. Romera, V. Pérez, A. Ciudad, L. Caballero, M. Roca, P. Polavieja, and I. Gilaberte Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis BMC Psychiatry 13 2013 51
29. I. Romera, V. Pérez, J.M. Menchón, A. Schacht, R. Papen, D. Neuhauser, M. Abbar, H. Picard, and I. Gilaberte Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study J. Affect. Disord. 143 2012 47 55
30. A.J. Rush, H.C. Draemer, H.A. Sackeim, and M. Fava Report by the ACNP task force on response and remission in major depressive disorder Neuropsychopharmacology 31 2006 1841 1853
31. A.J. Rush, M. Fava, S.R. Wisniewski, P.W. Lavori, M.H. Trivedi, H.A. Sackeim, M.E. Thase, A.A. Nierenberg, F.M. Quitkin, T.M. Kashner, D.J. Kupfer, J.F. Rosenbaum, J Alpert, J.W. Stewart, P.J. McGrath, M.M. Biggs, K. Shores-Wilson, B.D. Lebowitz, L. Ritz, G. Niederehe STARD Investigators Group Sequenced treatment alternatives to relieve depression (STARD): rationale and design Control Clin. Trials 25 2004 119 142
32. P. Sobocki, M. Ekman, H. Agren, M. Ekman, H. Agren, B. Runeson, and B. Jönsson The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression Int. J. Clin. Pract. 60 2006 791 798
33. M. Trivedi, A. Rush, S. Wisniewski, A.A. Nierenberg, D. Warden, L. Ritz, G. Norquist, R.H. Howland, B. Lebowitz, P.J. McGrath, K. Shores-Wilson, M.M. Biggs, G.K. Balasubramani, M. Fava STARD Study Team Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: implications for clinical practice Am. J. Psychiatry 163 2006 28 40
34. J.E. Ware Jr., and C.D. Sherbourne The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med. Care 30 1992 473 483
35. A.S. Zigmond, and R.P. Snaith The hospital anxiety and depression scale Acta Psychiatr. Scand. 67 1983 361 370